Antares Pharma (ATRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,321 | 46,289 | 13,606 | 8,213 | 3,793 |
| Depreciation Amortization | 931 | 3,901 | 2,761 | 1,815 | 894 |
| Income taxes - deferred | -817 | 13,939 | N/A | N/A | 590 |
| Accounts receivable | -1,434 | -14,476 | -12,250 | -12,007 | -731 |
| Accounts payable and accrued liabilities | 2,655 | 2,189 | -2,251 | -960 | 502 |
| Other Working Capital | -5,439 | 1,595 | 4,193 | -5,636 | -5,070 |
| Other Operating Activity | 1,544 | -16,818 | 21,068 | 16,986 | 2,000 |
| Operating Cash Flow | $-4,881 | $36,619 | $27,127 | $8,411 | $1,978 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 996 | N/A | 0 | N/A | 0 |
| PPE Investments | -81 | 11,208 | -4,960 | -2,457 | -1,184 |
| Purchase Of Investment | -249 | -1,245 | N/A | N/A | 0 |
| Purchase Sale Intangibles | N/A | -13,815 | N/A | N/A | N/A |
| Other Investing Activity | 0 | -13,815 | 0 | 0 | 0 |
| Investing Cash Flow | $666 | $-3,852 | $-4,960 | $-2,457 | $-1,184 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 20,000 | N/A | N/A | N/A |
| Debt Repayment | -375 | -42,055 | -20,200 | -15,000 | N/A |
| Common Stock Issued | 913 | 5,182 | 5,103 | 3,878 | 3,341 |
| Other Financing Activity | -521 | -3,117 | -2,841 | -2,841 | -1,619 |
| Financing Cash Flow | $17 | $-19,990 | $-17,938 | $-13,963 | $1,722 |
| Exchange Rate Effect | N/A | -1 | -1 | -2 | -1 |
| Beginning Cash Position | 65,913 | 53,137 | 53,137 | 53,137 | 53,137 |
| End Cash Position | 61,715 | 65,913 | 57,365 | 45,126 | 55,652 |
| Net Cash Flow | $-4,198 | $12,776 | $4,228 | $-8,011 | $2,515 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,881 | 36,619 | 27,127 | 8,411 | 1,978 |
| Capital Expenditure | -81 | -6,617 | -4,960 | -2,457 | -1,184 |
| Free Cash Flow | -4,962 | 30,002 | 22,167 | 5,954 | 794 |